NKTX
Price:
$5.32
Market Cap:
$375.37M
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on t...[Read more]
Industry
Biotechnology
IPO Date
2020-07-10
Stock Exchange
NASDAQ
Ticker
NKTX
According to Nkarta, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.70. This represents a change of -13.80% compared to the average of -3.13 of the last 4 quarters.
The mean historical PE Ratio of Nkarta, Inc. over the last ten years is -162.79. The current -2.70 PE Ratio has changed 65.86% with respect to the historical average. Over the past ten years (40 quarters), NKTX's PE Ratio was at its highest in in the September 2023 quarter at -0.66. The PE Ratio was at its lowest in in the March 2020 quarter at -40.48.
Average
-162.79
Median
-13.25
Minimum
-877.20
Maximum
-2.19
Discovering the peaks and valleys of Nkarta, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 25.80%
Maximum Annual PE Ratio = -2.19
Minimum Annual Increase = -92.24%
Minimum Annual PE Ratio = -877.20
Year | PE Ratio | Change |
---|---|---|
2023 | -2.75 | 25.80% |
2022 | -2.19 | -63.57% |
2021 | -6.01 | -70.68% |
2020 | -20.49 | -69.90% |
2019 | -68.09 | -92.24% |
The current PE Ratio of Nkarta, Inc. (NKTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.65
5-year avg
-19.91
10-year avg
-162.79
Nkarta, Inc.’s PE Ratio is greater than Monte Rosa Therapeutics, Inc. (-3.11), less than Lyell Immunopharma, Inc. (-1.42), less than Generation Bio Co. (-0.92), greater than Sana Biotechnology, Inc. (-4.82), less than Passage Bio, Inc. (0), less than Black Diamond Therapeutics, Inc. (-0.57), greater than TCR2 Therapeutics Inc. (-3.70), less than Harpoon Therapeutics, Inc. (-0.44), greater than Alector, Inc. (-2.94), greater than Century Therapeutics, Inc. (-2.92), less than Kezar Life Sciences, Inc. (-0.91), less than Mineralys Therapeutics, Inc. (-0.41), greater than NGM Biopharmaceuticals, Inc. (-4.63), less than Revolution Medicines, Inc. (-0.91), greater than Atreca, Inc. (-13.31), less than null (-0.04),
Company | PE Ratio | Market cap |
---|---|---|
-3.11 | $349.21M | |
-1.42 | $299.52M | |
-0.92 | $145.50M | |
-4.82 | $1.12B | |
0 | $43.48M | |
-0.57 | $305.13M | |
-3.70 | $58.11M | |
-0.44 | $865.08M | |
-2.94 | $472.01M | |
-2.92 | $123.69M | |
-0.91 | $40.82M | |
-0.41 | $558.43M | |
-4.63 | $128.53M | |
-0.91 | $6.99B | |
-13.31 | $3.57M | |
-0.04 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nkarta, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Nkarta, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Nkarta, Inc.'s PE Ratio?
How is the PE Ratio calculated for Nkarta, Inc. (NKTX)?
What is the highest PE Ratio for Nkarta, Inc. (NKTX)?
What is the 3-year average PE Ratio for Nkarta, Inc. (NKTX)?
What is the 5-year average PE Ratio for Nkarta, Inc. (NKTX)?
How does the current PE Ratio for Nkarta, Inc. (NKTX) compare to its historical average?